Scientists test if childhood meningitis shot needs a teen booster

NCT ID NCT06995430

Summary

This study is testing a booster dose of the meningitis B vaccine in healthy people aged 10 to 20 who received the same vaccine as infants. The goal is to see if the booster shot safely strengthens their immune defense against this serious infection. Researchers will compare the immune response in these individuals to others who have never received a meningitis B vaccine.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Espoo, 02230, Finland

  • GSK Investigational Site

    Helsinki, 00100, Finland

  • GSK Investigational Site

    Jarvenpaa, 04400, Finland

  • GSK Investigational Site

    Kokkola, 67100, Finland

  • GSK Investigational Site

    Oulu, 90220, Finland

  • GSK Investigational Site

    Seinäjoki, 60100, Finland

  • GSK Investigational Site

    Tampere, 33100, Finland

  • GSK Investigational Site

    Turku, 20520, Finland

  • GSK Investigational Site

    Florence, 50139, Italy

  • GSK Investigational Site

    Genova, 16132, Italy

  • GSK Investigational Site

    Milan, 20122, Italy

  • GSK Investigational Site

    Novara, 28100, Italy

  • GSK Investigational Site

    Santiago de Compostela, 15701, Spain

  • GSK Investigational Site

    Seville, 41014, Spain

  • GSK Investigational Site

    Bristol, BS2 8BJ, United Kingdom

  • GSK Investigational Site

    London, SW17 0RE, United Kingdom

  • GSK Investigational Site

    Oxford, OX3 7LE, United Kingdom

Conditions

Explore the condition pages connected to this study.